Back to top

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors

Keros Therapeutics, Inc. ($KROS) announced an update on their ongoing clinical study. The TROPOS study, officially titled “A Randomized, Phase 2, D...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Keros Therapeutics, Inc. (KROS)